GET THE APP

Recent Advancements in the Diagnosis, Prevention of Drug Therapy-COVID-19

Journal of Pharmaceutics & Drug Delivery Research .ISSN: 2325-9604

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Recent Advancements in the Diagnosis, Prevention of Drug Therapy-COVID-19

Severe acute metabolism syndrome coronavirus (CoV)-2 (SARS-CoV-2), antecedently referred to as 2019 novel CoV, emerged from China in late December 2019. This virus causes CoV disease-19 (COVID-19), that has been tried a world pandemic resulting in a serious occurrence. CoVs cause sicknesses that point severity from the communicable disease to severe metabolism sicknesses and death. notwithstanding, with technological advances and imperative lessons gained from previous outbreaks, mankind is best outfitted to take care of the most recent rising cluster of CoVs. Studies on the event of in vitro diagnostic tests, vaccines, and drug re-purposing square measure being administered during this field. Currently, no approved treatment is offered for SARS-CoV-2 given the shortage of proof. CoVs square measure a extremely varied cluster of positive-sense, enclosed fiber ribonucleic acid viruses. They cause varied diseases regarding metabolism, hepatic, medicine, and enteric systems of assorted severity amongst humans and animals.

Different human CoVs, as well as HCoV-OC43, HCoV-229E, HCoV-NL63, and HCoV-HKU1, cause an occasional incidence of metabolism infections and delicate malady. However, within the past many years, 2 deadly strains of CoVs, namely, Middle-East metabolism syndrome CoV (MERS-CoV) and SARS-CoV have emerged, inflicting severe infections in humans. The causative infective agent of COVID-19 is 2019-nCoV, that was initial detected in Gregorian calendar month 2020 and later termed as SARS-CoV-2. This infective agent may be a fiber ribonucleic acid virus that most likely originated from barmy because of its similar genetic sequence to different CoVs. though SARS-CoV-2 shares genetic options attuned with the opposite members of the CoV family, it possesses significantly varied genetic sequence compared therewith of earlier sequenced CoVs. SARS-CoV-2 shares around seventy nine.5% identical genetic sequence with SARS-CoV and ninety six.2% genetic sequence similarity with RaTG13, a brief ribonucleic acid-dependent RNA enzyme (RdRp) region gift within the CoV that originated from barmy.

Special Features

Full Text

View

Track Your Manuscript

Media Partners

Associations